| Case | Author | Gender | Age Smoking (years) | History | Histology | TNM staging | Mutated genes | Treatment | Response | PFS (month) | Os (month) |
| 1 | Chen, et al. | NA | NA | No | Adenocarcinoma | NA | RO51 EGFR (19del) | Gefitinib | PR | NA | NA |
| 2 | Chen, et al. | NA | NA | No | Adenocarcinoma | NA | RO51 EGFR(19del) | Gefitinib | PR | NA | NA |
| 3 | Chen, et al. | NA | NA | No | Adenocarcinoma | NA | ROS1 EGFR(19del) | NA | NA | NA | NA |
| 4 | Chen, et al. | NA | NA | No | Adenocarcinoma | NA | ROS1 EGFR (20-ins) | NA | NA | NA | NA |
| 5 | Mao, et al. | Female | 55 | No | Adenocarcinoma | NA | CD74-ROS1 EGFR(19del) | Crizotinib | 5D | 7.0 | 15.4 |
| 6 | Mao, et al. | Male | 45 | No | Adenocarcinoma | NA | EZR-ROS1 EGFR (19del) | Crizatinib | PR | 23.0 | 35 |
| 7 | Mao, et al. | Male | 59 | No | Adenocarcinoma | NA | CD74-ROS1 EGFR (L858R) | Crizatinib | PD | 2.0 | 24 |
| 8 | Zhu, et al. | Female | 50 | No | Adenocarcinoma with sarcomatoid differentiation | T2aNOMO stage Ib | CD74-ROS1 EGFR(L858R) | Postoperative chemotherapy | RO resectiona | NA | NA |
| 9 | present case | Female | 64 | No | Adenocarcinoma with sarcomatoid differentiation | T2N2MO stage IIIa | SLC34A2-ROS1 EGFR ARIDIA NFKBIA | Postoperative chemotherapy and radiotherapy | RO resectiona | NA | NA |